The clinical significance of expression of CD304 in B-cell acute lymphoblastic leukemia

ObjectiveTo investigate the clinical significance and application value of CD304 expression in B-cell acute lymphoblastic leukemia(B-ALL).

MethodsThe expression of CD304 in 32 newly diagnosed B-ALL patients, 5 T-cell acute lymphoblastic leukemia patients and 10 control cases with benign hematologic disease were tested by flow cytometry(FCM); 21 specimens in B-ALL patients with co-positive BCR-ABL and CD304 after treatment were detected for minimal residual disease(MRD) by FCM and PCR, and the coincidence rate was then compared.

ResultsThe positive rate of CD304 expression in BCR-ABL1 positive patients was higher than those in E2A-PbX1 and fusion gene-negative patients.CD304 were negative expression in T-ALL(n=5) and control groups(n=10).CD304 was positive in 43.75%(14/32) in newly diagnosed B-ALL cases, including 10 positive in 12 BCR-ABL, 1 positive in TEL-AML1, and 3 positive without fusion gene, while CD304 was negative in 3 E2A-PBX and 2 MLL/AF4 cases.The expression frequency of CD66c in CD304-positive B-ALL was increased(P < 0.05).As for MRD of 21 samples, 11 samples were PCR positive, 10 were FCM positive, 10 were double positive.Compared with PCR, the positive coincidence rare of FCM was 91% and total coincidence rare was 95%.

ConclusionsCD304 abnormal expressed in B-ALL has an important clinical value in the diagnosis and monitoring MRD.